{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:04:46Z","timestamp":1782313486481,"version":"3.54.5"},"reference-count":69,"publisher":"Elsevier BV","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMP"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Solanine was primarily known as a toxic compound. Nonetheless, recently the apoptotic role of solanine through suppression of PI3K\/AKT\/mTOR signaling pathway has been shown against many malignancies except chronic myelogenous leukemia (CML). Sustaining the aforementioned pro-survival pathway, BCR-ABL fused oncoprotein in CML activates NF-kB and c- MYC for apparent immortalizing factor hTERT. Since solanine is a poor water-soluble molecule, herein, a nanocarrier was employed to intensify its pernicious effect on cancerous cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>The current research aimed at evaluating the effect of dendrosomal nano solanine (DNS) on leukemic and HUVEC cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>DNS characterization was determined by NMR, DLS and TEM. The viability, apoptosis and cell cycle of DNS and imatinib-treated cells were determined. A quantitative real-time PCR was employed to measure the expression of PI3K, AKT, mTOR, S6K, NF-kB, c-MYC and hTERT mRNAs. The Protein levels were evaluated by western blot.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Investigating the anticancer property of free and dendrosomal nano solanine (DNS) and the feasible interplaying between DNS and imatinib on leukemic cells, we figured out the potential inhibitory role of DNS and DNS+IM on cancerous cells in comparison with chemotherapy drugs. Moreover, results revealed that the encapsulated form of solanine was much more preventive on the expression of PI3KCA, mTOR, NF-kB, c-MYC and hTERT accompanied by the dephosphorelating AKT protein.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>The results advocate the hypothesis that DNS, rather than solanine, probably due to impressive penetration, can restrain the principal pro-survival signaling pathway in erythroleukemia K562 and the HL60 cell lines and subsequently declined mRNA level of hTERT which causes drug resistance during long-term treatment. Additionally, combinational treatment of DNS and IM could also bestow an additive anti-leukemic effect. As further clinical studies are necessary to validate DNS efficacy on CML patients, DNS could have the potency to be considered as a new therapeutic agent even in combination with IM.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874467215666220516143155","type":"journal-article","created":{"date-parts":[[2022,5,17]],"date-time":"2022-05-17T07:55:20Z","timestamp":1652774120000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Anti-Cancer Role of Dendrosomal Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K\/AKT\/mTOR Signaling Pathway and Inhibition of hTERT Expression"],"prefix":"10.1016","volume":"16","author":[{"given":"Golareh","family":"Asgaritarghi","sequence":"first","affiliation":[{"name":"Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-1569","authenticated-orcid":true,"given":"Seyedeh Sahar Mortazavi","family":"Farsani","sequence":"additional","affiliation":[{"name":"Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Sadeghizadeh","sequence":"additional","affiliation":[{"name":"Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhood","family":"Naja\ufb01","sequence":"additional","affiliation":[{"name":"Department of Resin and Additives, Institute for Color Science and Technology, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Sadeghizadeh","sequence":"additional","affiliation":[{"name":"Department of Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1007\/s11033-014-3472-3","volume":"41","author":"Amini A.","year":"2014","unstructured":"Amini A.; Ghaffari S.H.; Mortazavi Y.; Daliri K.; Taranejoo S.; Alimoghadam K.; Ghavamzadeh A.; Expression pattern of hTERT telomerase subunit gene in different stages of chronic myeloid leukemia. Mol Biol Rep 2014,41(9),5557-5561","journal-title":"Mol Biol Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1535-7163.MCT-10-0979","volume":"10","author":"Deville L.","year":"2011","unstructured":"Deville L.; Hillion J.; Pendino F.; Samy M.; Nguyen E.; S&#xE9;gal-Bendirdjian E.; hTERT promotes imatinib resistance in chronic myeloid leukemia cells: Therapeutic implications. Mol Cancer Ther 2011,10(5),711-719","journal-title":"Mol Cancer Ther"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/jcb.22380","volume":"109","author":"Mancini M.","year":"2010","unstructured":"Mancini M.; Petta S.; Martinelli G.; Barbieri E.; Santucci M.A.; RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 2010,109(2),320-328","journal-title":"J Cell Biochem"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"Sawyers C.L.","year":"1999","unstructured":"Sawyers C.L.; Chronic myeloid leukemia. N Engl J Med 1999,340(17),1330-1340","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1182\/asheducation-2003.1.132","volume":"2003","author":"Melo J.V.","year":"2003","unstructured":"Melo J.V.; Hughes T.P.; Apperley J.F.; Chronic myeloid leukemia. Hematology (Am Soc Hematol Educ Program) 2003,2003(1),132-152","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.leukres.2007.08.009","volume":"32","author":"Jilani I.","year":"2008","unstructured":"Jilani I.; Kantarjian H.; Gorre M.; Cortes J.; Ottmann O.; Bhalla K.; Giles F.J.; Albitar M.; Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Leuk Res 2008,32(4),643-649","journal-title":"Leuk Res"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/84683","volume":"7","author":"Vigneri P.","year":"2001","unstructured":"Vigneri P.; Wang J.Y.; Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med 2001,7(2),228-234","journal-title":"Nat Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"Ren R.","year":"2005","unstructured":"Ren R.; Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005,5(3),172-183","journal-title":"Nat Rev Cancer"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2004-03-0849","volume":"105","author":"Kim J.H.","year":"2005","unstructured":"Kim J.H.; Chu S.C.; Gramlich J.L.; Pride Y.B.; Babendreier E.; Chauhan D.; Salgia R.; Podar K.; Griffin J.D.; Sattler M.; Activation of the PI3K\/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood 2005,105(4),1717-1723","journal-title":"Blood"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3389\/fonc.2014.00108","volume":"4","author":"Tasian S.K.","year":"2014","unstructured":"Tasian S.K.; Teachey D.T.; Rheingold S.R.; Targeting the PI3K\/mTOR pathway in pediatric hematologic malignancies. Front Oncol 2014,4,108","journal-title":"Front Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/leu.2011.46","volume":"25","author":"Martelli A.M.","year":"2011","unstructured":"Martelli A.M.; Evangelisti C.; Chappell W.; Abrams S.L.; B&#xE4;secke J.; Stivala F.; Donia M.; Fagone P.; Nicoletti F.; Libra M.; Ruvolo V.; Ruvolo P.; Kempf C.R.; Steelman L.S.; McCubrey J.A.; Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K\/PTEN\/Akt\/mTOR pathway. Leukemia 2011,25(7),1064-1079","journal-title":"Leukemia"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","volume":"72","author":"Bertacchini J.","year":"2015","unstructured":"Bertacchini J.; Heidari N.; Mediani L.; Capitani S.; Shahjahani M.; Ahmadzadeh A.; Saki N.; Targeting PI3K\/AKT\/mTOR network for treatment of leukemia. Cell Mol Life Sci 2015,72(12),2337-2347","journal-title":"Cell Mol Life Sci"},{"key":"ref=13","first-page":"819","volume":"955","author":"Park S.","year":"2010","unstructured":"Park S.; Role of the PI3K\/AKT and mTOR signaling pathways in acutemyeloid leukemia. haematologica. 2010,955(5),819-828"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011189","volume":"4","author":"Hemmings B.A.","year":"2012","unstructured":"Hemmings B.A.; Restuccia D.F.; PI3K-PKB\/Akt pathway. Cold Spring Harb Perspect Biol 2012,4(9)","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.gene.2012.01.095","volume":"498","author":"Daniel M.","year":"2012","unstructured":"Daniel M.; Peek G.W.; Tollefsbol T.O.; Regulation of the human catalytic subunit of telomerase (hTERT). Gene 2012,498(2),135-146","journal-title":"Gene"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.mrrev.2012.12.005","volume":"752","author":"Lamy E.","year":"2013","unstructured":"Lamy E.; Goetz V.; Erlacher M.; Herz C.; Mersch-Sundermann V.; hTERT: Another brick in the wall of cancer cells. Mutat Res Rev Mutat Res 2013,752(2),119-128","journal-title":"Mutat Res Rev Mutat Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1038\/sj.onc.1207582","volume":"23","author":"Kimura A.","year":"2004","unstructured":"Kimura A.; Ohmichi M.; Kawagoe J.; Kyo S.; Mabuchi S.; Takahashi T.; Ohshima C.; Arimoto-Ishida E.; Nishio Y.; Inoue M.; Kurachi H.; Tasaka K.; Murata Y.; Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines. Oncogene 2004,23(26),4505-4515","journal-title":"Oncogene"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"22886","DOI":"10.1038\/srep22886","volume":"6","author":"Liu H.","year":"2016","unstructured":"Liu H.; Liu Q.; Ge Y.; Zhao Q.; Zheng X.; Zhao Y.; hTERT promotes cell adhesion and migration independent of telomerase activity. Sci Rep 2016,6(1),22886","journal-title":"Sci Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"4121","DOI":"10.1007\/s00018-017-2573-2","volume":"74","author":"Lipinska N.","year":"2017","unstructured":"Lipinska N.; Romaniuk A.; Paszel-Jaworska A.; Toton E.; Kopczynski P.; Rubis B.; Telomerase and drug resistance in cancer. Cell Mol Life Sci 2017,74(22),4121-4132","journal-title":"Cell Mol Life Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s12013-011-9242-0","volume":"61","author":"Zhang Y.","year":"2011","unstructured":"Zhang Y.; Chen X.; Xu X.; Wang X.; Wang X.; Yuan G.; Sun D.; Ka W.; He D.; Wen Z.; Yao W.; Knockdown of hTERT alters biophysical properties of K562 cells resulting in decreased migration rate in vitro. Cell Biochem Biophys 2011,61(3),595-603","journal-title":"Cell Biochem Biophys"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"687","DOI":"10.3109\/10428194.2010.550978","volume":"52","author":"Varma N.","year":"2011","unstructured":"Varma N.; Anand M.S.; Varma S.; Juneja S.S.; Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia. Leuk Lymphoma 2011,52(4),687-693","journal-title":"Leuk Lymphoma"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-1119(01)00440-1","volume":"269","author":"Poole J.C.","year":"2001","unstructured":"Poole J.C.; Andrews L.G.; Tollefsbol T.O.; Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene 2001,269(1-2),1-12","journal-title":"Gene"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.canlet.2019.11.017","volume":"469","author":"Grandjenette C.","year":"2020","unstructured":"Grandjenette C.; Schnekenburger M.; Gaigneaux A.; G&#xE9;rard D.; Christov C.; Mazumder A.; Dicato M.; Diederich M.; Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells. Cancer Lett 2020,469,468-480","journal-title":"Cancer Lett"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1006\/clim.1999.4769","volume":"93","author":"Han S-S.","year":"1999","unstructured":"Han S-S.; Chung S.T.; Robertson D.A.; Ranjan D.; Bondada S.; Curcumin causes the growth arrest and apoptosis of B cell lymphoma by downregulation of egr-1, c-myc, bcl-XL, NF-&#x3BA; B, and p53. Clin Immunol 1999,93(2),152-161","journal-title":"Clin Immunol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1002\/jcp.23029","volume":"227","author":"Ciarcia R.","year":"2012","unstructured":"Ciarcia R.; Vitiello M.T.; Galdiero M.; Pacilio C.; Iovane V.; d\u2019Angelo D.; Pagnini D.; Caparrotti G.; Conti D.; Tomei V.; Florio S.; Giordano A.; Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol 2012,227(6),2798-2803","journal-title":"J Cell Physiol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.canlet.2009.05.028","volume":"286","author":"Moon D-O.","year":"2009","unstructured":"Moon D-O.; Kim M.O.; Lee J.D.; Choi Y.H.; Kim G.Y.; Butein suppresses c-Myc-dependent transcription and Akt-dependent phosphorylation of hTERT in human leukemia cells. Cancer Lett 2009,286(2),172-179","journal-title":"Cancer Lett"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/nrc904","volume":"2","author":"Pelengaris S.","year":"2002","unstructured":"Pelengaris S.; Khan M.; Evan G.; c-MYC: More than just a matter of life and death. Nat Rev Cancer 2002,2(10),764-776","journal-title":"Nat Rev Cancer"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"Deininger M.W.","year":"2000","unstructured":"Deininger M.W.; Goldman J.M.; Melo J.V.; The molecular biology of chronic myeloid leukemia. Blood 2000,96(10),3343-3356","journal-title":"Blood"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/med.21346","volume":"36","author":"Jiang Q.W.","year":"2016","unstructured":"Jiang Q.W.; Chen M.W.; Cheng K.J.; Yu P.Z.; Wei X.; Shi Z.; Therapeutic potential of steroidal alkaloids in cancer and other diseases. Med Res Rev 2016,36(1),119-143","journal-title":"Med Res Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1248\/bpb.33.1685","volume":"33","author":"Lu M-K.","year":"2010","unstructured":"Lu M-K.; Shih Y.W.; Chang C.; T.T.; Fang, L.H.; Huang, H.C.; Chen, P.S. &#x3B1;-Solanine inhibits human melanoma cell migration and invasion by reducing matrix metalloproteinase-2\/9 activities. Biol Pharm Bull 2010,33(10),1685-1691","journal-title":"Biol Pharm Bull"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"6437","DOI":"10.1007\/s13277-015-4528-2","volume":"37","author":"Zhang F.","year":"2016","unstructured":"Zhang F.; Yang R.; Zhang G.; Cheng R.; Bai Y.; Zhao H.; Lu X.; Li H.; Chen S.; Li J.; Wu S.; Li P.; Chen X.; Sun Q.; Zhao G.; Anticancer function of &#x3B1;-solanine in lung adenocarcinoma cells by inducing microRNA-138 expression. Tumour Biol 2016,37(5),6437-6446","journal-title":"Tumour Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejphar.2013.09.015","volume":"718","author":"Mohsenikia M.","year":"2013","unstructured":"Mohsenikia M.; Alizadeh A.M.; Khodayari S.; Khodayari H.; Kouhpayeh S.A.; Karimi A.; Zamani M.; Azizian S.; Mohagheghi M.A.; The protective and therapeutic effects of alpha-solanine on mice breast cancer. Eur J Pharmacol 2013,718(1-3),1-9","journal-title":"Eur J Pharmacol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jep.2007.09.023","volume":"115","author":"Ji Y.B.","year":"2008","unstructured":"Ji Y.B.; Gao S.Y.; Ji C.F.; Zou X.; Induction of apoptosis in HepG2 cells by solanine and Bcl-2 protein. J Ethnopharmacol 2008,115(2),194-202","journal-title":"J Ethnopharmacol"},{"key":"ref=34","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/805926","author":"Sun H.","year":"2014","unstructured":"Sun H.; Solanine induces mitochondria-mediated apoptosis in human pancreatic cancer cells 2014","journal-title":"Solanine induces mitochondria-mediated apoptosis in human pancreatic cancer cells"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.3748\/wjg.v12.i21.3359","volume":"12","author":"Gao S-Y.","year":"2006","unstructured":"Gao S-Y.; Wang Q-J.; Ji Y-B.; Effect of solanine on the membrane potential of mitochondria in HepG2 cells and [Ca2+]i in the cells. World J Gastroenterol 2006,12(21),3359-3367","journal-title":"World J Gastroenterol"},{"key":"ref=36","first-page":"1","author":"Hassan S.H.","year":"2020","unstructured":"Hassan S.H.; Alpha Solanine: A novel natural bioactive molecule with anticancer effects in multiple human malignancies. Nutr Cancer 2020,1-12","journal-title":"Nutr Cancer"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"e1860","DOI":"10.1038\/cddis.2015.219","volume":"6","author":"Hasanain M.","year":"2015","unstructured":"Hasanain M.; Bhattacharjee, A.; Pandey, P.; Ashraf, R.; Singh, N.; Sharma, S.; Vishwakarma, A.L.; Datta, D.; Mitra, K.; Sarkar, J. &#x3B1;-Solanine induces ROS-mediated autophagy through activation of endoplasmic reticulum stress and inhibition of Akt\/mTOR pathway. Cell Death Dis 2015,6(8),e1860-e1860","journal-title":"Cell Death Dis"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.lfs.2016.02.008","volume":"148","author":"Mohsenikia M.","year":"2016","unstructured":"Mohsenikia M.; Farhangi B.; Alizadeh A.M.; Khodayari H.; Khodayari S.; Khori V.; Arjmand Abbassi Y.; Vesovic M.; Soleymani A.; Najafi F.; Therapeutic effects of dendrosomal solanine on a metastatic breast tumor. Life Sci 2016,148,260-267","journal-title":"Life Sci"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S63762","volume":"9","author":"Erfani-Moghadam V.","year":"2014","unstructured":"Erfani-Moghadam V.; Nomani A.; Zamani M.; Yazdani Y.; Najafi F.; Sadeghizadeh M.; A novel diblock of copolymer of (monomethoxy poly [ethylene glycol]-oleate) with a small hydrophobic fraction to make stable micelles\/polymersomes for curcumin delivery to cancer cells. Int J Nanomedicine 2014,9,5541-5554","journal-title":"Int J Nanomedicine"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s00249-006-0042-1","volume":"35","author":"Alexiou C.","year":"2006","unstructured":"Alexiou C.; Schmid R.J.; Jurgons R.; Kremer M.; Wanner G.; Bergemann C.; Huenges E.; Nawroth T.; Arnold W.; Parak F.G.; Targeting cancer cells: Magnetic nanoparticles as drug carriers. Eur Biophys J 2006,35(5),446-450","journal-title":"Eur Biophys J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-018-0805-1","volume":"17","author":"Massimino M.","year":"2018","unstructured":"Massimino M.; Stella S.; Tirr&#xF2; E.; Romano C.; Pennisi M.S.; Puma A.; Manzella L.; Zangh&#xEC; A.; Stagno F.; Di Raimondo F.; Vigneri P.; Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia. Mol Cancer 2018,17(1),56","journal-title":"Mol Cancer"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1021\/mp100455h","volume":"8","author":"Misra R.","year":"2011","unstructured":"Misra R.; Sahoo S.K.; Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells. Mol Pharm 2011,8(3),852-866","journal-title":"Mol Pharm"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.18388\/abp.2007_3181","volume":"54","author":"Jakubowska J.","year":"2007","unstructured":"Jakubowska J.; Stasiak M.; Szulawska A.; Bednarek A.; Czyz M.; Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562. Acta Biochim Pol 2007,54(4),839-846","journal-title":"Acta Biochim Pol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ajh.25011","volume":"93","author":"Jabbour E.","year":"2018","unstructured":"Jabbour E.; Kantarjian H.; Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring. Am J Hematol 2018,93(3),442-459","journal-title":"Am J Hematol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"Mosmann T.","year":"1983","unstructured":"Mosmann T.; Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983,65(1-2),55-63","journal-title":"J Immunol Methods"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10637-007-9099-7","volume":"26","author":"Walters D.K.","year":"2008","unstructured":"Walters D.K.; Muff R.; Langsam B.; Born W.; Fuchs B.; Cytotoxic effects of curcumin on osteosarcoma cell lines. Invest New Drugs 2008,26(4),289-297","journal-title":"Invest New Drugs"},{"key":"ref=47","first-page":"14","volume":"4","author":"Berridge M.V.","year":"1996","unstructured":"Berridge M.V.; The biochemical and cellular basis of cell proliferation assays that use tetrazolium salts. Biochemica (Indianap, Ind) 1996,4(1),14-19","journal-title":"Biochemica (Indianap, Ind)"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"Deininger M.W.","year":"2020","unstructured":"Deininger M.W.; Shah N.P.; Altman J.K.; Berman E.; Bhatia R.; Bhatnagar B.; DeAngelo D.J.; Gotlib J.; Hobbs G.; Maness L.; Mead M.; Metheny L.; Mohan S.; Moore J.O.; Naqvi K.; Oehler V.; Pallera A.M.; Patnaik M.; Pratz K.; Pusic I.; Rose M.G.; Smith B.D.; Snyder D.S.; Sweet K.L.; Talpaz M.; Thompson J.; Yang D.T.; Gregory K.M.; Sundar H.; Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2020,18(10),1385-1415","journal-title":"J Natl Compr Canc Netw"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11912-018-0669-y","volume":"20","author":"Breccia M.","year":"2018","unstructured":"Breccia M.; Fo&#xE0; R.; Current information and recommendations on the discontinuation of TKI inhibitors in chronic myeloid leukemia. Curr Oncol Rep 2018,20(3),23","journal-title":"Curr Oncol Rep"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1038\/s41375-020-0842-9","volume":"34","author":"Hochhaus A.","year":"2020","unstructured":"Hochhaus A.; Breccia M.; Saglio G.; Garc&#xED;a-Guti&#xE9;rrez V.; R&#xE9;a D.; Janssen J.; Apperley J.; Expert opinion-management of chronic myeloid leukemia after resistance to second-generation tyrosine kinase inhibitors. Leukemia 2020,34(6),1495-1502","journal-title":"Leukemia"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/cells9020379","volume":"9","author":"Sarno F.","year":"2020","unstructured":"Sarno F.; Pepe G.; Termolino P.; Carafa V.; Massaro C.; Merciai F.; Campiglia P.; Nebbioso A.; Altucci L.; Trifolium Repens blocks proliferation in chronic myelogenous leukemia via the BCR-ABL\/STAT5 pathway. Cells 2020,9(2),379","journal-title":"Cells"},{"key":"ref=52","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.108656","volume":"112","author":"Yang J.","year":"2019","unstructured":"Yang J.; Hao T.; Sun J.; Wei P.; Zhang H.; Long noncoding RNA GAS5 modulates &#x3B1;-Solanine-induced radiosensitivity by negatively regulating miR-18a in human prostate cancer cells. Biomed Pharmacother 2019,112","journal-title":"Biomed Pharmacother"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3892\/or.2020.7519","volume":"43","author":"Yan X.","year":"2020","unstructured":"Yan X.; Li, M.; Chen, L.; Peng, X.; Que, Z.J.; An, H.M.; Shen, K.P.; Hu, B. &#x3B1; Solanine inhibits growth and metastatic potential of human colorectal cancer cells. Oncol Rep 2020,43(5),1387-1396","journal-title":"Oncol Rep"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1080\/01635581.2020.1803932","volume":"73","author":"Hassan S.H.","year":"2021","unstructured":"Hassan S.H.; Gul S.; Zahra H.S.; Maryam A.; Shakir H.A.; Khan M.; Irfan M.; Alpha solanine: A novel natural bioactive molecule with anticancer effects in multiple human malignancies. Nutr Cancer 2021,73(9),1541-1552","journal-title":"Nutr Cancer"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/toxins13030210","volume":"13","author":"Gu T.","year":"2021","unstructured":"Gu T.; Yuan, W.; Li, C.; Chen, Z.; Wen, Y.; Zheng, Q.; Yang, Q.; Xiong, X.; Yuan, A. &#x3B1;-solanine inhibits proliferation, invasion, and migration, and induces apoptosis in human choriocarcinoma jeg-3 cells in vitro and in vivo. Toxins (Basel) 2021,13(3),210","journal-title":"Toxins (Basel)"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1365-2125.2006.02713.x","volume":"62","author":"Kummar S.","year":"2006","unstructured":"Kummar S.; Gutierrez M.; Doroshow J.H.; Murgo A.J.; Drug development in oncology: Classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006,62(1),15-26","journal-title":"Br J Clin Pharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.phymed.2015.05.071","volume":"22","author":"Zamani M.","year":"2015","unstructured":"Zamani M.; Sadeghizadeh M.; Behmanesh M.; Najafi F.; Dendrosomal curcumin increases expression of the long non-coding RNA gene MEG3 via up-regulation of epi-miRs in hepatocellular cancer. Phytomedicine 2015,22(10),961-967","journal-title":"Phytomedicine"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijpharm.2016.05.039","volume":"509","author":"Montazeri M.","year":"2016","unstructured":"Montazeri M.; Sadeghizadeh M.; Pilehvar-Soltanahmadi Y.; Zarghami F.; Khodi S.; Mohaghegh M.; Sadeghzadeh H.; Zarghami N.; Dendrosomal curcumin nanoformulation modulate apoptosis-related genes and protein expression in hepatocarcinoma cell lines. Int J Pharm 2016,509(1-2),244-254","journal-title":"Int J Pharm"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"5886","DOI":"10.1128\/MCB.01265-07","volume":"28","author":"Hui R.C-Y.","year":"2008","unstructured":"Hui R.C-Y.; Gomes A.R.; Constantinidou D.; Costa J.R.; Karadedou C.T.; Fernandez de Mattos S.; Wymann M.P.; Brosens J.J.; Schulze A.; Lam E.W.; The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase\/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 2008,28(19),5886-5898","journal-title":"Mol Cell Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/(SICI)1097-4652(199611)169:2<256::AID-JCP5>3.0.CO;2-N","volume":"169","author":"Wang T.S.","year":"1996","unstructured":"Wang T.S.; Kuo C.F.; Jan K.Y.; Huang H.; Arsenite induces apoptosis in Chinese hamster ovary cells by generation of reactive oxygen species. J. Cell. Physiol. 1996,169(2),256-268"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.916","volume":"5","author":"Pan B.","year":"2016","unstructured":"Pan B.; Zhong W.; Deng Z.; Lai C.; Chu J.; Jiao G.; Liu J.; Zhou Q.; Inhibition of prostate cancer growth by solanine requires the suppression of cell cycle proteins and the activation of ROS\/P38 signaling pathway. Cancer Med 2016,5(11),3214-3222","journal-title":"Cancer Med"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.3892\/ol.2016.4167","volume":"11","author":"Meng X.Q.","year":"2016","unstructured":"Meng X.Q.; Zhang W.; Zhang F.; Yin S.Y.; Xie H.Y.; Zhou L.; Zheng S.S.; Solanine-induced reactive oxygen species inhibit the growth of human hepatocellular carcinoma HepG2 cells. Oncol Lett 2016,11(3),2145-2151","journal-title":"Oncol Lett"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3892\/etm.2016.3500","volume":"12","author":"Wang L.","year":"2016","unstructured":"Wang L.; Sun Q.Q.; Zhang S.J.; Du Y.W.; Wang Y.Y.; Zang W.Q.; Chen X.N.; Zhao G.Q.; Inhibitory effect of &#x3B1;-solanine on esophageal carcinoma in vitro. Exp Ther Med 2016,12(3),1525-1530","journal-title":"Exp Ther Med"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cyto.a.20357","volume":"71","author":"Kajstura M.","year":"2007","unstructured":"Kajstura M.; Halicka H.D.; Pryjma J.; Darzynkiewicz Z.; Discontinuous fragmentation of nuclear DNA during apoptosis revealed by discrete &#x201C;sub-G1&#x201D; peaks on DNA content histograms. Cytometry A 2007,71(3),125-131","journal-title":"Cytometry A"},{"key":"ref=65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174446","volume":"910","author":"Kayabasi C.","year":"2021","unstructured":"Kayabasi C.; Yelken B.O.; Asik A.; Okcanoglu T.B.; Sogutlu F.; Gasimli R.; Susluer S.Y.; Saydam G.; Avci C.B.; Gunduz C.; PI3K\/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia. Eur J Pharmacol 2021,910","journal-title":"Eur J Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"30438","DOI":"10.18632\/oncotarget.16737","volume":"8","author":"Xu X.","year":"2017","unstructured":"Xu X.; Sun J.; Song R.; Doscas M.E.; Williamson A.J.; Zhou J.; Sun J.; Jiao X.; Liu X.; Li Y.; Inhibition of p70 S6 kinase (S6K1) activity by A77 1726, the active metabolite of leflunomide, induces autophagy through TAK1-mediated AMPK and JNK activation. Oncotarget 2017,8(18),30438-30454","journal-title":"Oncotarget"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12032-021-01462-5","volume":"38","author":"Singh P.","year":"2021","unstructured":"Singh P.; Kumar V.; Gupta S.K.; Kumari G.; Verma M.; Combating TKI resistance in CML by inhibiting the PI3K\/Akt\/mTOR pathway in combination with TKIs: A review. Med Oncol 2021,38(1),10","journal-title":"Med Oncol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.21873\/anticanres.13657","volume":"39","author":"DE. Holanda","year":"2019","unstructured":"DE. Holanda; L.S.; Mesquita, F.P.; DE Moraes-Filho, M.O.; DE Moraes, M.E.A.; Montenegro, R.C.; DE Sousa Portilho, A.J.; Moreira-Nunes, C.A. Characterization of telomerase (HTERT) in solid and hematopoietic cancer cell lines reveals different expression patterns. Anticancer Res 2019,39(9),4743-4748","journal-title":"Anticancer Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/978-3-642-75889-8_27","author":"Duyao M.","year":"1990","unstructured":"Duyao M.; Binding of NF-KB-like factors to regulatory sequences of the c-myc gene Mechanisms in B-Cell Neoplasia 1990 1990,211-220","journal-title":"Binding of NF-KB-like factors to regulatory sequences of the c-myc gene Mechanisms in B-Cell Neoplasia 1990"}],"container-title":["Current Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467215666220516143155","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/204855\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1874467215666220516143155","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T22:58:08Z","timestamp":1746572288000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/204855\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":69,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874467215666220516143155","relation":{},"ISSN":["1874-4672"],"issn-type":[{"value":"1874-4672","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-06-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-05","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e160522204855"}}